Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 4/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905502 | 0.88 | CA12 (0.41) | GGT1ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL20477159 | 0.88 | CA12 (0.41) | GGT1ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL27650325 | 0.85 | GGT1 (0.55) | GGT1ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL27902177 | 0.85 | GGT1 (0.46) | GGT1CPB2CPB1 | |
| SCHEMBL27650327 | 0.85 | GGT1 (0.55) | GGT1ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL30885854 | 0.84 | MAOA (0.48) | ECE1MAOAMAOB | |
| SCHEMBL3441239 | 0.83 | ECE1 (0.38) | ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL1221420 | 0.83 | ECE1 (0.38) | ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL10724429 | 0.82 | GGT1 (0.46) | GGT1MAOAMAOBCPB2CPB1 | |
| SCHEMBL29670111 | 0.82 | GGT1 (0.40) | GGT1ECE1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |